Pediatric Critical Illness Hyperglycemia and Glycemic Control Registry
Recruitment status was Recruiting
The objective in this project is to assemble a consortium of pediatric critical care centers of varying size, acuity, and composition to evaluate our glycemic control protocol on at least 250 children with hyperglycemia in different critical care units.
***This Study is supported by an R21 Grant (MRR) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
|Study Design:||Observational Model: Case-Only|
|Official Title:||Pediatric Critical Illness Hyperglycemia and Glycemic Control Registry: A Project to Assist in the Improved Understanding of Hyperglycemia and Glycemic Control in Pediatric Critical Illness.|
- Identify and manage hyperglycemia in pediatric intensive care unit [ Time Frame: 5-2012 ] [ Designated as safety issue: Yes ]Determine safety (ie hypoglycemia) and effectiveness (ie ability to establish/maintain glycemic control) of our pedatric-specific approach to control critical illness hyperglycemia.
- Consortium of centers practiced at glycemic control in pediatric intensive care unit. [ Time Frame: 5-2012 ] [ Designated as safety issue: Yes ]To develop a consortium of centers that will be practiced at glycemic control who may be able to participate in a future multi-center trial in glycemic control. To use the experience of other centers to refine a generalizable protocol to successfully and safely control hyperglycemia.
|Study Start Date:||May 2010|
|Estimated Study Completion Date:||May 2013|
|Estimated Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of > 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is > 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
Many studies over the past decade have demonstrated that clinical outcomes can be improved in critically ill adults by aggressive management of hyperglycemic with insulin infusions (Van Den Berghe 2001, Van Den Berghe 2006, Krinsey 2004, Treggari 2008, Scalea, 2007, Lang 2007). Yet, in some of these studies and other recent trials (i.e. Glucontrol (Preiser, 2009) VISEP (Brunkhorst, 2008) and (NICE-SUGAR, 2009)), have highlighted the potential and real risks of glycemic control (namely iatrogenic hypoglycemia) and questioned how effectively glucose can be controlled in critical illness. One reason for the suboptimal glycemic control witnessed in some trials may be not rigorously refined and validated. Even as such, many medical oversight committees (including the Institutes of Healthcare Improvement, the American Diabetes Association, and Society of Critical Care Medicine, among others) continue to recommend regular and aggressive glycemic control in critically ill patients. Although not specifically included nor excluded from such recommendations, most pediatric intensivists have not incorporated glycemic control into regular practice primarily due to concerns of therapy induced hyperglycemia - although there are reports of protocols that appear to be effective at controlling BG levels with low rates of hypoglycemia (Preissig et al 2008, Verhoeven et al 2009).
Our group at Emory University and Children's' Healthcare of Atlanta has taken a progressive, yet methodical, approach to better understand the implications of hyperglycemia and its treatment in critically ill and injured children. Practitioners at our facility developed a pediatric-specific protocol to identify and treat hyperglycemia in critically ill children. We have instituted this approach as standard care in our facility and have experience with managing several hundred children with hyperglycemia. Our approach to glycemic management has very promising safety and efficacy profiles, even when compared to the most stringent and successful glycemic control protocols used in adults. We published the first experience in pediatric glycemic control in pediatric in 2008 (Preissig et al PCCM 2008) and have used our experience to identify specific risk factors for developing hypoglycemia (Preissig et al JPed, 2009).
The goal of this proposal is to assist our step-wise approach in investigating hyperglycemia in critically ill children by externally validating our glycemic control protocol via multi-center evaluation. In doing so, we will also be developing the infrastructure and a tested intervention that can be leveraged for future studies of hyperglycemia in pediatric critical illness, including a multi-center outcome trial. The specific hypothesis for this project is that our protocol is safe and efficient at identifying and managing hyperglycemia in critically ill or injured children in pediatric ICUs regardless of ICU size, acuity, model, staffing makeup, or clinical focus.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01116674
|Contact: Daniel C Keeton, BAfirstname.lastname@example.org|
|United States, Georgia|
|Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit||Recruiting|
|Atlanta, Georgia, United States, 30308|
|Contact: Jeryl Huckaby, RRT 404-785-0040 email@example.com|
|Principal Investigator: Kevin O Maher, MD|
|Children's Healthcare of Atlanta at Egleston - Pediatric Intensive Care Unit||Recruiting|
|Atlanta, Georgia, United States, 30308|
|Contact: Daniel C Keeton, BA 404-785-6027 firstname.lastname@example.org|
|Principal Investigator: Mark R Rigby, MD, PhD|
|Medical Center of Central Georgia - Pediatric Intensive Care Unit||Recruiting|
|Macon, Georgia, United States, 31201|
|Contact: Catherine M Pressig, MD 770-653-6203 email@example.com|
|Principal Investigator: Catherine M Pressig, MD|
|Principal Investigator:||Mark R Rigby, MD, PhD||Emory University and Children's Healthcare of Atlanta at Egleston|
|Study Director:||Cathering M Preissig, MD (Co-I)||Medical Center of Central Georgia|
|Study Director:||Kevin O Maher, MD (Co-I)||Emory University and Children's Healthcare of Atlanta at Egleston|
|Study Director:||Daniel C Keeton, BA (Coordinator)||Children's Healthcare of Atlanta at Egleston and Emory University|
|Study Director:||Jeryl Huckaby, RRT (Coordinator)||Children's Healthcare of Atlanta at Egleston and Emory University|